Gujarat Themis Biosyn profitability ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025

Returns
	17.4%	17.4%	19.6%
	11.6%	11.6%	16.2%
	17.8%	17.8%	22.6%
	11.4%	10.6%	17.7%
Margins
	47.4%	45.6%	45.7%
	37.8%	37.8%	42.1%
	—	−5.7%	—
	37.5%	37.4%	43.5%
	28.0%	28.2%	32.3%
	−74.6%	−74.6%	−16.7%
Additional
	25.3%	24.8%	25.6%
	—	15.6%	3.7%
	17.4%	14.7%	18.9%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

GUJTHEM₹355.55

Gujarat Themis Biosyn Limited

· Pharma & Health

₹ CrorePeersRPGLIFE GUFICBIO ORCHPHARMA UNICHEMLAB FDC IOLCP MOREPENLAB INNOVACAPMcap ₹3,874 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Returns
Return on Common Equity	19.64	17.41	17.41
Return on Assets	16.19	11.60	11.60
Return on Capital Employed	22.61	17.76	17.76
Return on Invested Capital	17.72	10.59	11.36
Margins
EBITDA Margin	45.65	45.55	47.43
Operating Margin	42.09	37.76	37.76
Incremental Operating Margin	—	-5.72	—
Pretax Margin	43.46	37.44	37.49
Net Income Margin	32.34	28.15	28.02
FCF Margin	-16.66	-74.63	-74.63
Additional
Effective Tax Rate	25.58	24.82	25.25
Dvd Payout Ratio	3.72	15.64	—
Sustainable Growth Rate	18.91	14.69	17.41

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.